Nom du produit:2-Fluoro-4-iodoaniline
IUPAC Name:2-fluoro-4-iodoaniline
- CAS：29632-74-4
- Formule moléculaire：C6H5FIN
- Pureté：95%+
- Numéro de catalogue：CM118182
- Poids moléculaire：237.02
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:29632-74-4
- Formule moléculaire:C6H5FIN
- Point de fusion:-
- Code SMILES:NC1=CC=C(I)C=C1F
- Densité:
- Numéro de catalogue:CM118182
- Poids moléculaire:237.02
- Point d'ébullition:261.7°C at 760 mmHg
- N° Mdl:MFCD00011738
- Stockage:Keep in dark place, store at 2-8°C.
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Nitrogen Compounds
- Nitrogen compounds can be classified as mineral or organic. Mineral compounds are essentially formed by the ammonium ion (NH4+), which is generated when ammonium salts are dissolved in water. Organic compounds, in contrast, are carbon and hydrogen compounds that contain a nitrogen atom. All organic nitrogen-containing compounds can be considered as derivatives of ammonia in which one or more hydrogen atoms are substituted by hydrocarbon radicals.
- Mirdametinib
- SpringWorks Therapeutics announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The NDA submission includes data from the Phase 2b ReNeu trial. The primary endpoint was confirmed objective response rate (ORR). The BICR-confirmed objective response rate was 52% in pediatric patients and 41% in adult patients. Mirdametinib treatment showed deep and durable responses and demonstrated significant improvements in key secondary patient-reported outcome measures.
Recherche 
+86 21 5895 0110 
